ClinicalTrials.gg

Program

efimosfermin alfa

Also written as “Efimosfermin alfa”, “Efimosfermin” and “Efimosfermin Alfa”.

In GlaxoSmithKline's pipeline, Fibroblast growth factor 21 (FGF21) analog. Its studies are mostly in Non-alcoholic Fatty Liver Disease · Fatty Liver · Liver Diseases, Alcoholic · Obesity, led by 2 companies.

Furthest: phase 3, since Oct 15, 202510 company-led studies, 7 open or runningNext primary completion: Oct 13, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline97 open or runningphase 3since Oct 15, 2025May 5, 2021Oct 13, 2027phase 1 · NCT07358546
Novartis10 open or runningphase 1since Feb 9, 2018Feb 9, 2018none ahead
  • Named in GlaxoSmithKline’s own pipeline as efimosfermin alfa GSK6519754, phase 3, as of Sep 30, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 9, 2018First study: phase 1 study in ObesityNew to NovartisNovartis · NCT03466203 · 61 enrolled · United States
  2. May 5, 2021GlaxoSmithKline's first study: phase 2 study in Non-alcoholic Fatty Liver DiseaseNew to GlaxoSmithKlineGlaxoSmithKline · NCT04880031 · 231 enrolled · United States
  3. Mar 26, 2025Phase 2 study in Non-alcoholic Fatty Liver DiseaseGlaxoSmithKline · NCT06920043 · 42 planned · United States
  4. Oct 15, 20252 phase 3 studies in Non-alcoholic Fatty Liver DiseaseGlaxoSmithKline · NCT07221227, NCT07221188
  5. Jan 5, 20262 phase 1 studies in Non-alcoholic Fatty Liver DiseaseGlaxoSmithKline · NCT07335198, NCT07358546
  6. Jul 9, 20262 phase 3 studiesGlaxoSmithKline · NCT07701993, NCT07704892
  7. Aug 21, 2026Phase 2 study in Liver Diseases, AlcoholicGlaxoSmithKline · NCT07791043 · 274 planned · United States, Argentina, Canada and more

Ahead

  1. Oct 13, 2027Primary completion: phase 1 study in Non-alcoholic Fatty Liver DiseaseGlaxoSmithKline · NCT07358546
  2. Mar 24, 2028Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseGlaxoSmithKline · NCT07221188
  3. Mar 29, 2028Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseGlaxoSmithKline · NCT07221227
  4. Jul 3, 2028Primary completion: phase 2 study in Non-alcoholic Fatty Liver DiseaseGlaxoSmithKline · NCT06920043

TargetBeta

“Fibroblast growth factor 21 (FGF21) analog”the company's pipeline, read by Claude · source

Other programs on FGF21

ProgramCompanyFurthest phaseStudies
pegozafermin89bio-incphase 38
efruxiferminNovo Nordiskphase 36
zalferminNovo Nordiskphase 210

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07791043Liver Diseases, Alcoholic · United States, Argentina, Canada and more2RecruitingGlaxoSmithKlineAug 11, 2028274
NCT07704892Fibrosis · United States, Japan3RecruitingGlaxoSmithKlineOct 16, 2030380
NCT07701993Fatty Liver · United States, Japan3RecruitingGlaxoSmithKlineJun 23, 20331,740
NCT07358546Non-alcoholic Fatty Liver Disease · United States1RecruitingGlaxoSmithKlineOct 13, 202732
NCT07335198Non-alcoholic Fatty Liver Disease · New Zealand1CompletedGlaxoSmithKlineAug 13, 202630
NCT07221227Non-alcoholic Fatty Liver Disease · United States, Australia, Canada and more3RecruitingGlaxoSmithKlineMar 29, 20281,200
NCT07221188Non-alcoholic Fatty Liver Disease · United States, Australia, France and more3RecruitingGlaxoSmithKlineMar 24, 20281,250
NCT06920043Non-alcoholic Fatty Liver Disease · United States2RecruitingGlaxoSmithKlineJul 3, 202842
NCT04880031Non-alcoholic Fatty Liver Disease · United States2CompletedGlaxoSmithKlineOct 27, 2025231
NCT03466203Obesity · United States1CompletedNovartisNov 13, 201961

How it is read

Names in the registry

  • “Efimosfermin alfa”, 7 entries
  • “Efimosfermin”, 2 entries
  • “Efimosfermin Alfa”, 1 entry
  • “LLF580”, 1 entry

Codes read as this program: BOS580.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.